宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01541 宜明昂科-B

未开盘 09-02 16:08:05

3.600

-0.100

-2.70%

最高3.710	最低3.570	成交量39.78万
今开3.710	昨收3.700	日振幅3.78%
总市值15.44亿	流通市值15.05亿	总股本4.29亿
成交额145.03万	换手率0.10%	流通股本4.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"宜明昂科-B","latestPrice":3.6,"timestamp":1788336485683,"preClose":3.7,"halted":0,"volume":397800,"delay":0,"changeRate":-0.02702702702702705,"floatShares":418000000,"shares":429000000,"eps":-0.6186720618564786,"marketStatus":"未开盘","change":-0.1,"latestTime":"09-02 16:08:05","open":3.71,"high":3.71,"low":3.57,"amount":1450287,"amplitude":0.037838,"askPrice":3.66,"askSize":7000,"bidPrice":3.6,"bidSize":41400,"shortable":0,"etf":0,"ttmEps":-0.6329949037413446,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788399000000},"marketStatusCode":0,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":3.7,"openAndCloseTimeList":[[1788312600000,1788321600000],[1788325200000,1788336000000]],"volumeRatio":0.364205669063711,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01541","defaultTab":"news","newsList":[{"id":"2662004094","title":"宜明昂科-B(01541.HK)：提名刘秀枝担任独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2662004094","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662004094?lang=zh_cn&edition=full","pubTime":"2026-08-28 23:33","pubTimestamp":1787931233,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154767258","title":"宜明昂科-B（01541）拟更换独董 朱禎平辞任、刘秀枝获提名接任","url":"https://stock-news.laohu8.com/highlight/detail?id=1154767258","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154767258?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:15","pubTimestamp":1787926542,"startTime":"0","endTime":"0","summary":"2026年8月28日，宜明昂科生物医药技术（上海）股份有限公司发布公告称，公司董事会收到独立非执行董事朱禎平博士的辞任申请，理由为其需投入更多时间于其他商业事务。朱博士将继续履行相关职务直至股东大会选举出新任独立非执行董事之日，届时其辞任即时生效，并同时卸任董事会审计委员会、薪酬委员会及提名委员会成员。公司董事会确认，朱博士与董事会无意见分歧，亦无任何需提请香港联合交易所有限公司或股东注意的其他事项。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196464406","title":"宜明昂科-B（01541）披露IMM2510联合IMM27M一线治疗晚期肝细胞癌II期临床试验完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1196464406","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196464406?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:22","pubTimestamp":1787836942,"startTime":"0","endTime":"0","summary":"2026年8月27日，宜明昂科生物医药技术（上海）股份有限公司发布自愿公告称，IMM2510联合IMM27M一线治疗晚期肝细胞癌的II期临床试验已完成首例患者给药。该研究主要评估该联合疗法在HCC患者中的初步疗效与安全性。公司自2023年首次提交IMM2510联合IMM27M的试验性新药申请以来，临床开发进展稳定。根据香港联交所证券上市规则第18A.05条的警示声明，公司无法保证能够成功开发或最终上市销售IMM2510联合IMM27M。公司提醒股东及潜在投资者在买卖公司股份时保持审慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662008845","title":"宜明昂科-B(01541)：IMM2510联合IMM27M一线治疗晚期HCC的II期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2662008845","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662008845?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:21","pubTimestamp":1787836891,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，IMM2510联 合 IMM27M一线治疗晚期肝细胞癌患者的II期临床试验顺利完成首例患者给药。该研究旨在评估IMM2510联合IMM27M在该患者群体中的初步疗效及安全性。自2023年首次提交IMM2510联合IMM27M的试验性新药申请以来，该联合疗法的临床开发稳步推进，并展现出卓越的潜力。令人鼓舞的早期临床结果证实，IMM2510联合IMM27M在晚期实体瘤治疗中具有显著的抗肿瘤活性及可控的安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCC","BK4006","PSYK","IBBJ","01541","MDTX","COAL","BK1161","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662440778","title":"宜明昂科-B午后涨超10% 上半年公司实现收入2542.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662440778","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662440778?lang=zh_cn&edition=full","pubTime":"2026-08-27 13:46","pubTimestamp":1787809560,"startTime":"0","endTime":"0","summary":"模拟交易客户端宜明昂科-B盘中大涨近12%，截至发稿，股价上涨10.27%，现报4.08港元，成交额623.90万港元。8月26日晚，宜明昂科发布2026年中期业绩，今年上上半年，公司实现收入2542.4万元，主要来自与Axion Bio订立的授权及合作协议收取的付款。公司现金储备保持充沛。截至2026年6月30日，公司现金及现金等价物、按公允价值计量的金融资产及原到期日三个月以上的定期存款合计约9.47亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-27/doc-inipttca0918508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662672478","title":"港股异动 | 宜明昂科-B(01541)涨近12% 公司现金储备保持充沛 多项关键临床试验达重要节点","url":"https://stock-news.laohu8.com/highlight/detail?id=2662672478","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662672478?lang=zh_cn&edition=full","pubTime":"2026-08-27 10:49","pubTimestamp":1787798975,"startTime":"0","endTime":"0","summary":"宜明昂科-B(01541)大涨近12%，截至发稿，涨10.41%，报4.085港元，成交额342.9万港元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260827/20260827104951_52940.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260827/20260827104951_52940.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IBBJ","VXUS","IBBQ","01541","KCAI","BK4588","BK4585","BMED","BK1161","MDTX","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662717577","title":"宜明昂科-B(01541)发布中期业绩 实现收入2542.4万元 多项关键临床试验达到重要节点","url":"https://stock-news.laohu8.com/highlight/detail?id=2662717577","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662717577?lang=zh_cn&edition=full","pubTime":"2026-08-26 21:51","pubTimestamp":1787752295,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布截至2026年6月30日止6个月中期业绩，收入2542.4万元;研发开支1.55亿元，同比减少7.9%。公告称，收入截至2026年6月30日止6个月为人民币2542.4万元，主要归因于根据公司于2024年与Axion Bio, Inc.订立的授权及合作协议收取的付款。于报告期间，公司持续快速推进药物管线的开发，在肿瘤免疫治疗及自身免疫性疾病领域均取得重要里程碑及成就。IMM01、IMM0306 及IMM2510等主要临床阶段资产取得重大进展，多项关键临床试验达到重要节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK1161","IBBJ","01541","PSYK","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120373006","title":"宜明昂科-B2026年中期营收25.4百万元，经调整净亏损1.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120373006","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120373006?lang=zh_cn&edition=full","pubTime":"2026-08-26 21:48","pubTimestamp":1787752124,"startTime":"0","endTime":"0","summary":"2026年上半年，宜明昂科-B公告显示，公司实现营收25.4百万元，同比下降约33.2%。期内经调整净亏损1.62亿元，较上年同期的1.44亿元亏损规模扩大约12.5%。经营活动现金流出净额为1.60亿元，上一年同期为1.31亿元。行政开支为23.2百万元，同比下降14.9%，主要因为以股份为基础的非现金开支有所减少。其中，合作开发贡献的收入为25.25百万元，相比上年同期的37.99百万元减少，主要受此前已确认的授权合作款差异影响。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"宜明昂科-B2026年中期营收25.4百万元，经调整净亏损1.62亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662735752","title":"宜明昂科-B(01541)：IMC-003的PAH试验完成首例患者给药以及SAD及MAD剂量组入组完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2662735752","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662735752?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:41","pubTimestamp":1787654497,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，IMC-003/IMM72已取得两项重要临床里程碑。在肺动脉高压患者中开展的Ib/IIa期临床试验完成首例受试者入组及给药，标志着IMC-003临床开发正式迈向患者验证阶段。IMC-003在8mg/kg剂量水平下总体耐受性良好，未报告剂量限制性毒性事件。与研究药物相关的所有不良事件中绝大部分为1级，且未报告与治疗相关的3级或以上的AE。至此，方案设计的所有剂量组已完成入组。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IMC","BK1161","BK4168","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197906279","title":"宜明昂科-B（01541）IMC-003临床再获进展：PAH首例患者完成给药，I期SAD及MAD全部剂量组入组结束","url":"https://stock-news.laohu8.com/highlight/detail?id=1197906279","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197906279?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:40","pubTimestamp":1787654451,"startTime":"0","endTime":"0","summary":"2026年8月25日，宜明昂科生物医药技术（上海）股份有限公司发布自愿公告，披露其自主研发的激活素受体IIA-Fc融合蛋白IMC-003/IMM72在临床开发中取得两项关键里程碑进展。公司根据香港联合交易所证券上市规则第18A.05条作出风险提示：目前无法保证IMC-003最终能够成功开发并上市销售。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661667298","title":"宜明昂科-B(01541.HK)：美国食药监局批准IMM0306治疗系统性红斑狼疮的 Ib/II期临床试验IND申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2661667298","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661667298?lang=zh_cn&edition=full","pubTime":"2026-08-21 20:33","pubTimestamp":1787315587,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165566391","title":"宜明昂科-B获FDA批准开展IMM0306治疗系统性红斑狼疮Ib/II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1165566391","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165566391?lang=zh_cn&edition=full","pubTime":"2026-08-21 20:15","pubTimestamp":1787314535,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司8月21日自愿公告称，公司已收到美国食品药品监督管理局关于IMM0306用于治疗系统性红斑狼疮Ib/II期临床试验的试验性新药申请批准。根据公告，IMM0306为公司自主研发的、同时靶向分化簇47和分化簇20的双特异性分子，是全球首个进入临床阶段的CD47/CD20双靶向候选药物。目前，公司拥有IMM0306的全球知识产权及商业化权利。公告日期为2026年8月21日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142353157","title":"宜明昂科-B（01541.HK）获FDA批准IMM0306 IND申请，推进系统性红斑狼疮Ib/II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1142353157","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142353157?lang=zh_cn&edition=full","pubTime":"2026-08-21 20:14","pubTimestamp":1787314453,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药（上海）股份有限公司传来重磅消息——其核心在研产品IMM0306的新药临床试验申请已正式获得美国食品药品监督管理局的批准。这一绿灯放行，意味着该药物针对系统性红斑狼疮的Ib/II期临床研究即将拉开帷幕。此次FDA的批准，无疑为这家聚焦创新免疫疗法的生物科技公司注入了强劲动力。从监管层面的积极反馈来看，IMM0306在治疗自身免疫性疾病领域的潜力获得了权威认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168082510","title":"宜明昂科-B（01541）拟于2026年8月26日召开董事会审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1168082510","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168082510?lang=zh_cn&edition=full","pubTime":"2026-08-14 16:47","pubTimestamp":1786697234,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司（01541）8月14日公告，公司董事会将于2026年8月26日（星期三）召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其刊发事宜，并同步考虑建议派发中期股息（如有）。\n截至公告日期，董事会成员包括：执行董事田文志、李松、关梅及张如亮；非执行董事徐聪、付大伟；独立非执行董事朱禎平、Kendall Arthur Smith及杨志达。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969219","title":"港股午评|恒生指数早盘跌0.63%    CRO概念继续走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969219","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658969219?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:00","pubTimestamp":1786420834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数跌0.63%，跌163点，报25773点；恒生科技指数跌1.27%。港股早盘成交1158亿港元。药明康德司法取得进展，有利于CXO公司在海外争取新的订单。再鼎医药涨超5%，Q2产品收入环比增长11%，花旗看好中国业务下半年企稳。津上机床中国涨超5%，电子与AI液冷两大领域在新订单占比约四成。黄金股普遍承压。油价走高加剧通胀上行担忧，美联储鹰派释放强硬信号。中国黄金国际跌2.5%；紫金矿业跌3.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0588546209.SGD","LU0164939612.USD","LU0737861772.HKD","SG9999003461.SGD","LU2488822045.USD","LU0266512127.USD","688234","BK1588","LU0509642566.USD","02026","LU0329678170.USD","LU0287142896.SGD","LU0417516902.SGD","BK1592","03115","BK1576","02631","06616","LU0868486357.SGD","03419","688062","SG9999001093.SGD","LU1303224171.USD","LU0821914370.USD","LU0348827113.USD","BK1594","LU1224709979.USD","LU0173614495.USD","02837","HK0000306685.HKD","HK0000306701.USD","03423","LU0348767384.USD","LU0278937759.USD","06821","LU2226246903.HKD","LU0737861699.HKD","LU0269904917.USD","LU0634319403.HKD","BK1544","02800","BK1587","LU1808992512.USD","07200","HSI","LU0431992006.USD","LU0211977185.USD","LU2097828805.USD","BK1129","LU2460026573.USD","LU0326950275.SGD","07500","LU0149721374.USD","JINFF","LU0181495838.USD","HK0000320223.HKD","LU1770034418.SGD","LU1961090484.USD","513600","09067","03759","02899","07552","07226","LU0048580855.USD","LU0140636845.USD","LU0307460666.USD","LU0106959298.USD","LU0082770016.USD","01548","LU0871576103.HKD","300759","LU2097828631.EUR","LU2097828557.USD","LU2177674079.SGD","LU0328353924.USD","03417","LU1720050803.USD","LU0828237940.HKD","LU0348816934.USD","LU2264538146.SGD","02099","02833","LU0061477393.USD","LU0164880469.USD","LU1831875114.USD","LU1719994722.HKD","LU0165289439.USD","LU0345780281.USD","LU1282648689.USD","LU1769817096.USD","LU0327786744.USD","LU0531971595.HKD","03033","LU0082770016.SGD","LU1988902786.USD","LU0456854461.SGD","LU1188198961.HKD","07300","LU0348735423.USD","LU1251922891.USD","09088","BK1583","82800","LU0348766576.USD","LU2399975544.HKD","LU1481107354.HKD","06951","ZIJMY","BK1170","BK1161","LU0039217434.USD","02493","LU0348825331.USD","LU0828237510.HKD","LU0572944931.SGD","BK1183","BK1190","LU0049853897.USD","LU0370786039.SGD","BK1169","LU0463099449.HKD","LU1048596156.SGD","03032","09115","LU0918141705.HKD","SG9999004220.SGD","LU0329678337.USD","LU0540923850.HKD","MCHmain","LU0620787316.HKD","LU2039709279.SGD","IE0032431581.USD","BK1505","LU0469268626.HKD","LU0561508036.HKD","09688","LU1105468828.SGD","BK1191","BK1198","LU0266512473.USD","PONY","LU1242518857.USD","LU1064131342.USD","BK1109","01651","HK0000320264.USD","LU0043850808.USD","LU0417516738.SGD","ZLAB","LU0918141887.USD","601899","LU2008162690.USD","LU0797268264.HKD","01541","LU1794554557.SGD","BK1574","002821","LU1769817179.HKD","83115","LU2097828474.EUR","300408","LU0828238088.HKD","HHImain","LU1504937902.USD","BK1141","LU0348814723.USD","03037","LU3063872942.SGD","LU0979878070.USD","LU0096374516.USD","SG9999002463.SGD","LU0274383008.USD","LU1242518931.SGD","HSTECH","03067","LU0345780521.USD","LU0244354667.USD","LU0886674414.USD","LU0106252389.USD","LU0228659784.USD","03088","LU2097828714.EUR","LU0164865239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658966148","title":"港股异动 | 宜明昂科-B(01541)再涨超14% 宜明凯尔首次引入外部商业化资本 加速非肿瘤管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2658966148","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658966148?lang=zh_cn&edition=full","pubTime":"2026-08-11 10:53","pubTimestamp":1786416803,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B再涨超14%，截至发稿，涨10.78%，报3.495港元，成交额313.68万港元。消息面上，宜明昂科发布公告称，附属宜明凯尔与生科起航、新界创元及王雪岩订立增资协议，三名投资者合共以总代价5,000万元人民币，认缴宜明凯尔的46.5万元经扩大注册资本，约占其经扩大股权的15.83%。通过首次引入外部商业化资本，宜明凯尔成功实现了向多元化股权结构的转变，旨在加速其在肺动脉高压等心血管疾病和代谢性疾病领域的创新药研发进程。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478348.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","BK1161","KCAI","VXUS","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658661459","title":"港股异动 | 宜明昂科-B(01541.HK)再涨超14% 宜明凯尔首次引入外部商业化资本 加速非肿瘤管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2658661459","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658661459?lang=zh_cn&edition=full","pubTime":"2026-08-11 10:53","pubTimestamp":1786416803,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657691835","title":"港股异动 | 宜明昂科-B(01541)午后涨近10% 附属宜明凯尔5000万战略增资 加速非肿瘤管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2657691835","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657691835?lang=zh_cn&edition=full","pubTime":"2026-08-07 13:41","pubTimestamp":1786081269,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B(01541)午后涨近10%，截至发稿，涨8.42%，报3.155港元，成交额156.61万港元。消息面上，宜明昂科发布公告称，附属宜明凯尔与生科起航、新界创元及王雪岩订立增资协议，三名投资者合共以总代价5,000万元人民币，认缴宜明凯尔的46.5万元经扩大注册资本，约占其经扩大股权的15.83%。公开资料显示，宜明凯尔专注于肺动脉高压等心血管疾病及代谢疾病领域大分子药物的研发。本次增资旨在进一步充实宜明凯尔的财务资源，加速其在肺动脉高压等心血管疾病及代谢疾病领域的创新药研发进程，标志着宜明昂科“肿瘤+非肿瘤”双轮驱动战略的稳步落地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477198.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1161","KCAI","BK4585","01541","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661971","title":"宜明昂科-B(01541)附属宜明凯尔生物医药技术(上海)获增资5000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661971","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657661971?lang=zh_cn&edition=full","pubTime":"2026-08-07 06:57","pubTimestamp":1786057046,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，于2026年8月6日，本公司、宜明凯尔生物医药技术(上海)有限公司、嘉兴张科领弋生科起航创业投资合伙企业、苏州新界创元企业管理合伙企业及王雪岩先生订立增资协议。根据增资协议，投资者同意以总对价人民币5000万元认缴合共人民币46.5万元经扩大注册资本，约占目标公司经扩大股权的15.83%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399441","BK1161","BK4581","BK4588","01541","XBI","161726","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129045886","title":"宜明昂科-B2026年7月股份变动月报：回购580,000股H股，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1129045886","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129045886?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:41","pubTimestamp":1786005709,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年8月6日发布2026年7月股份变动月报。本月报显示，公司于截止2026年7月31日的注册股本总额为人民币431,507,695元，其中H股注册股本数为420,477,305股，非上市股份注册股本数为11,030,390股。股份变动方面，本月内未有新增发行；公司购回H股580,000股，并将其列作库藏股份。截至本月底，公司H股已发行股份由上月底的419,035,505股调整至418,455,505股，库藏股份由1,441,800股增至2,021,800股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://immuneonco.com","stockEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":0.1632},{"period":"3month","weight":0.1576},{"period":"6month","weight":-0.1874},{"period":"1year","weight":-0.673},{"period":"ytd","weight":-0.3825}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0268},{"period":"3month","weight":0.0023},{"period":"6month","weight":-0.0173},{"period":"1year","weight":-0.0073},{"period":"ytd","weight":-0.0125}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"宜明昂科生物医药技术（上海）股份有限公司是一家主要从事开发肿瘤免疫疗法的中国公司。该公司的主要业务包括开发用于系统利用先天性和适应性免疫的生物技术，以及开发下一代肿瘤免疫疗法，免疫疗法主要专注于适应性免疫系统。该公司的核心产品IMM01是创新靶向CD47的分子。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.125053},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.059944},{"month":3,"riseRate":0.666667,"avgChangeRate":-0.036378},{"month":4,"riseRate":0.666667,"avgChangeRate":0.020918},{"month":5,"riseRate":0.333333,"avgChangeRate":0.218025},{"month":6,"riseRate":0.333333,"avgChangeRate":0.064638},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.092027},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.068233},{"month":9,"riseRate":0.666667,"avgChangeRate":0.070469},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.115476},{"month":11,"riseRate":0,"avgChangeRate":-0.146508},{"month":12,"riseRate":0,"avgChangeRate":-0.128943}],"exchange":"SEHK","name":"宜明昂科-B","nameEN":"IMMUNEONCO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宜明昂科-B,01541,宜明昂科-B股票,宜明昂科-B股票老虎,宜明昂科-B股票老虎国际,宜明昂科-B行情,宜明昂科-B股票行情,宜明昂科-B股价,宜明昂科-B股市,宜明昂科-B股票价格,宜明昂科-B股票交易,宜明昂科-B股票购买,宜明昂科-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}